Closed-loop control of emotional state
A device that senses a person's affective state and stimulates to drive it to a chosen setpoint, on demand and reversibly.
State of the art
Chronic sense-and-stimulate implant delivered biomarker-driven therapy for treatment-resistant depression (Nature Medicine 2021); Medtronic adaptive DBS approved February 2025.
- Controlling severity of illness is not the same as selecting an arbitrary mood; the control space is undemonstrated
- Tolerance, rebound and hedonic habituation under repeated stimulation are unmeasured
- Open-loop safety; a device that can induce despair as easily as calm has no fail-safe design yet
Who’s working on it
- Katherine ScangosResearcherUCSF
Showed biomarker-triggered amygdala-guided stimulation relieved treatment-resistant depression in one patient (Nature Medicine 2021)
- Motif Neurotech ↗Startup
Received FDA IDE in April 2026 for RESONATE, a trial of its blueberry-sized wireless DOT stimulator for depression; raised $30M+
- Inner Cosmos ↗Startup
Completed an FDA early feasibility study of a minimally invasive skull-embedded depression stimulator in 2025
- MedtronicCompany
BrainSense adaptive DBS, the first sensing closed-loop DBS, was FDA-approved for Parkinson's in February 2025
- Helen MaybergResearcherIcahn School of Medicine at Mount Sinai
Subcallosal cingulate DBS pioneer; runs sensing-DBS studies of moment-to-moment mood signals
- Nudge ↗Startup
Raised a $100M Series A in 2025 for wearable focused-ultrasound deep-brain stimulation, targeting mood and addiction among other uses
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Primate and patient studies that attempt setpoint control of discrete affective states with objective readouts | $$ $10M – $100M |
| engineering | Implant and wearable controllers with certified fail-safe limits on stimulation of affective circuits | $$ $10M – $100M |
Depends on
Required by
No other capability builds on this directly.